BMC Gastroenterology · 2021 · 16 citations · 25 references
Life SciencesImmunologyPathologyGastroenterologyInflammationMucosal ImmunologyGastrointestinal ImmunologyGastrointestinal InflammationInflammatory Bowel DiseaseInflammatory PathologyMucosal Cytokine NetworksMucosal InflammationClinical RemissionHistologic RemissionInflammatory Bowel Disease ImmunopathogenesisInflammatory Bowel Disease PathogenesisInflammatory Bowel Disease PathophysiologyInterleukin-12 SignalingReal-time Polymerase Chain Reaction (Pcr)Ulcerative Colitis Pathology
BACKGROUND: The role of IL-12/23 in the pathogenesis of ulcerative colitis (UC) is unclear. We analyzed mucosal IL-12/23 expression and its relationship with endoscopic severity, histological activity, and UC relapse. METHODS: Rectal biopsies were collected from 70 UC patients with clinical remission. IL-12, IL-23, IFN-γ, IL-17A, and IL-17F mRNA expression was measured by real-time PCR. Endoscopic severity and histological activity were evaluated using the Mayo endoscopic subscore (MES) and the Geboes score, respectively. RESULTS: The longest follow-up period was 51 months. Thirty-four patients relapsed during the study period. Samples from these subsequently relapsed patients formed the "relapse" group, while those from patients that did not relapse formed the "remission" group. IL-12 (P = 0.0003) and IL-23 (P = 0.014) mRNA expression was significantly higher in the relapse than the remission group. Expression of IL-23 (P = 0.015) but not IL-12 (P = 0.374) was correlated with MES. However, in patients with an MES of 0 and 1, IL-12 expression was statistically higher in the relapse than the remission group (P = 0.0015, P = 0.0342). IL-12 and IL-23 expression did not vary significantly between histologically active and inactive mucosa; both were higher in histologically inactive patients in the remission group (IL-12: P = 0.0002, IL-23: P = 0.046). CONCLUSIONS: Rectal IL-12 and IL-23 expression was elevated in the relapse group, but IL-12 was more strongly associated with UC relapse, irrespective of endoscopic severity and histological activity. Mucosal IL-12 was elevated in patients with deep mucosal healing. Our results suggest an important role of IL-12 in UC pathogenesis and the molecular mechanism of UC relapse.
25
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands et al. · New England Journal of Medicine · 2013 · 2.9K citations · Full text
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn, Brian G. Feagan, Paul Rutgeerts et al. · New England Journal of Medicine · 2013 · 2.7K citations · Full text
Michiko Kobayashi, Lori Fitz, Michael P. Ryan et al. · The Journal of Experimental Medicine · 1989 · 2K citations · Full text
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Brian G. Feagan, William J. Sandborn, Christopher Gasink et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Simon Lichtiger, D. H. Present, Asher Kornbluth et al. · New England Journal of Medicine · 1994 · 1.7K citations